US10246414B2 – April 2, 2019 – Allosteric modulators of CB1 cannabinoid receptors

Please complete the required fields.




Inventors :

Ganeshsingh A. Thakur; Pushkar M. Kulkarni

Owner :

NORTHEASTERN UNIVERSITY

Application Number :

US15416311

Document Number :

US10246414B2

Priority Date :

January 26, 2017

Filing Date :

January 26, 2017

Date of Grant/ Publication :

April 2, 2019

Class :

; A61K31 / 404; C07D209 / 10; C07D401 / 06; C07D209 / 14; C07D401 / 10

Abstract

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

Claim(s)

1. A pharmaceutical composition for treatment of Huntington’s disease, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof: and a pharmaceutically-acceptable carrier or diluent.;
2. A pharmaceutical composition for treatment of Huntington’s disease or glaucoma, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof: and a pharmaceutically acceptable carrier or diluent.;
3. A pharmaceutical composition for treatment of Huntington’s disease, pain, neuropathic pain, glaucoma, post-traumatic stress disorder, or epileptic seizure, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof: and a pharmaceutically acceptable carrier or diluent.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login